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Rocuronium, one of the most common neuromuscular 
blockade agents which is used for facilitating 
intubation for general anaesthesia, poses risks of 
residual paralysis. Residual paralysis after rocuronium 
blockade in the recovery room occurs in around 56.5% 
of patients, and it can increase the incidence of airway 
obstruction, hypoxaemia and postoperative pulmonary 
complications,[1,2] as well as delayed recovery room 
discharge.[3] However, despite these risks, it has not 
been widely considered as an important patient safety 
concern.[4]
Less residual paralysis was demonstrated when 
quantitative neuromuscular monitoring was 
applied.[5,6] However, the device is not widely available 
with only 9.4–22.7% of clinicians who had quantitative 
train-of-four (TOF) monitoring in their practice.[7,8] 
When it is not available, the chance of successful 
reversal may be increased by optimal administration 
of neostigmine, a reversal agent for neuromuscular 
blockade that has been used for decades.[9] Recent 
studies showed that the depth of blockade-based 
neostigmine dosing and reversal-extubation time 
have an important role in decreasing incidence of 
Original Article
Ardyan Wardhana, Juni Kurniawaty, Yusmein Uyun
Department of Anaesthesiology and Intensive Therapy, Faculty of Medical, Public Health and Nursing, 
University of Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, Indonesia
Optimised reversal without train‑of‑four monitoring 
versus reversal using quantitative train‑of‑four 
monitoring: An equivalence study
ABSTRACT
Background and Aims: Less residual paralysis in recovery room was demonstrated when 
train-of-four (TOF) monitoring was applied. The aim of this study was to know whether optimisation 
of neostigmine reversal without TOF monitoring was equivalent to reversal using TOF monitoring. 
Methods: Seventy two patients, aged 18–60 years, undergoing elective surgery under general 
anaesthesia (sevoflurane and rocuronium) with intubation were randomised into two interventions: 
an optimised neostigmine reversal strategy without TOF monitoring (group A, n = 36) and a 
neostigmine reversal strategy using quantitative TOF monitoring (group B, n = 36). Per-protocol 
analysis was performed to compare incidence of residual paralysis in the recovery room between 
the two groups. Results: Six residual paralyses occurred in group A in the recovery room, whereas 
one case occurred in group B. The equivalence test showed that the 95% confidence interval of 
this study was outside the range of equivalence margin (15%). The absolute difference was 13.9%: 
standard error (SE) =0.068 (P = 0.107; 95% confidence interval (CI): 1%, 27.2%). No subjects had 
TOF ratio <0.70 in the recovery room. The TOF ratio in the recovery room did not differ between 
the two groups (mean difference: −2.58; P = 0.05; 95% CI: −5.20, 0.29). One respiratory adverse 
event occurred in this study. Conclusion: An optimised reversal strategy without TOF monitoring 
is not equivalent to a reversal strategy based on quantitative TOF monitoring. TOF monitoring 
should be used whenever applicable, although neostigmine is optimised.
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residual paralysis.[10-12] The depth of blockade might be 
determined through tidal volume parameters.[8]
The outcome of optimising neostigmine reversal 
strategy without TOF monitoring has never been 
studied. This study tested whether optimisation of 
neostigmine reversal strategy without TOF monitoring 
was equivalent to neostigmine reversal strategy using 
TOF monitoring to be able to inform clinical decision 
making where neuromuscular monitoring is not 
available.
METHODS
The study was conducted at a tertiary care hospital 
during May–July 2018. The study was approved by 
the Medical and Health Research Ethics Committee of 
FKKMK UGM and Dr. Sardjito Hospital. This trial was 
registered in UMIN clinical trials registry (https://www.
umin.ac.jp/ctr). Informed consents were acquired 
from all subjects before participating in this study. 
The patients included for the study aged 18–60 years, 
with American Society of Anesthesiologists’ (ASA) 
I–II physical status and who were going to undergo 
elective non-head/neck surgery using general 
anaesthesia with intubation. Exclusion criteria were 
elective surgery <1 h duration; awake extubation or 
postsurgery intensive care admission; body mass index 
>35 kg/m2; hepatic disease (liver enzyme value >50% 
normal value); renal insufficiency (serum creatinine 
>1.8 mg/dL); neuromuscular disease; consumption of 
drugs known to affect neuromuscular transmission; 
contraindications to neostigmine and/or atropine 
sulphate; a history of hypersensitivity or allergic to 
anaesthetic agent given and difficulty accessing the 
TOF measuring device in the ulnar nerve.
The study subjects were allocated into two groups 
using stratified randomisation based on the type of 
surgery. Group A received optimal neostigmine reversal 
strategy without TOF monitoring, whereas group B 
had reversal strategy based on TOF quantitative 
monitoring. The allocated group information was 
given in a sealed envelope when the patient arrived at 
the surgery room.
In preoperative room, subjects were given midazolam 
2 mg intravenous (IV). Anaesthesia was induced 
with propofol 1–2 mg/kg IV, fentanyl 100 µg IV and 
rocuronium 0.6–0.8 mg/kg IV for tracheal intubation. 
Anaesthesia was maintained with sevoflurane 1–3% 
with delivery gas N2O/O2 in the ratio 50:50. Sevoflurane 
concentration was set to maintain the bispectral index 
values 40–60 and mean arterial pressure (MAP) in the 
range of 20% base value. Ventilation was adjusted to 
maintain ETCO2 in the range of 35–45 mmHg.
All subjects had two electrodes on the forearm. Distal 
electrode was placed at the wrist crest, whereas the 
proximal electrode was placed 3–6 cm proximal from 
the distal one. The thumb should be able to move 
freely and the other finger was fixed to the arm of bed. 
For group B, all TOF-Watch SX device cables (Organon, 
Inc., Dublin, Ireland) were then connected to the 
electrodes and the transducer was taped to the distal 
phalanx of the thumb.
Additional rocuronium was given if there was 
an indication and given as much as 10 mg after a 
spontaneous breathing was detected or the time of last 
rocuronium administration was more than 30 min. 
Towards the end of the surgery, the first researcher 
opened the envelope. Then, the reversal management 
using neostigmine was done, as shown in Figure 1. 
Atropine sulphate 10 µg/kg IV was given to every 
subject receiving neostigmine.
In group A, the first researcher counted the time since 
last rocuronium administration and assessed the 
subject’s spontaneous breathing effort. The reversal 
strategy was based on the facts that the duration of 
action of rocuronium is equal to TOF count of 4; tidal 
volume returns to normal when TOF ratio is >0.40 
and diaphragm muscles fully recover if TOF ratio 
is >0.70.[12-14] In addition, reversal attempt should 
be delayed by at least 30 min after rocuronium 
administration if there is no sign of recovery.[12] When 
the time of last rocuronium was >30 min without 
evidence of spontaneous breathing, neostigmine 
50 µg/kg IV was given. When minimal spontaneous 
breathing was detected, neostigmine was given 
30–40 µg/kg IV and 20–30 µg/kg if last rocuronium 
was	 given	 ≤30	 min	 and	 ≥30	 min	 before	 reversal,	
respectively. Subjects received neostigmine 10 µg/kg 
IV if they had adequate spontaneous breathing pattern.
In group B, neostigmine was given at a dose according 
to the measured TOF value.[13] TOF stimulation of 
50 mA was given without calibration. Neostigmine 
administration was delayed if TOF count value was 
0–1. Subjects who had TOF count of 2–4 received 
50 µg/kg	 IV	 of	 neostigmine.	 If	 TOF	 ratio	was	≤0.40	
and in the range 0.40–0.70, then neostigmine dosing 
of 40 and 20–30 µg/kg IV, respectively, was given. 
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Neostigmine was administered 10 µg/kg IV if subject 
had minimal block.
The primary outcome was the proportion of subjects 
who have residual paralysis in the recovery room 
based on the threshold TOF value <0.90 in both 
groups. Oxygen supplementation via nasal cannula 
3–4 L/min, SpO2, ECG and non-invasive blood pressure 
monitoring devices and TOF-Watch SX devices were 
installed on all subjects on arrival at the recovery 
room, and the TOF value was measured by the second 
researcher who did not know the type of intervention 
given. Measurements were done twice consecutively 
over 12 s. The value used was the average of both 
values. However, if the difference was more than 10%, 
the measurement was done twice more in the same 
way. The value collected was the average of the two 
closest values. All subjects were monitored for airway 
problems, respiration patterns, oxygen saturation, 
nausea and vomiting during 30 min in the recovery 
room.
Equivalence tests were used based on the assumption 
that new interventions using optimal reversal strategies 
without TOF monitoring offer ease of application 
during surgery and can be used for most practices with 
limited availability of TOF monitoring devices. The 
margin of equivalency was 15%, which was a derived 
value determined as half of the margin of superiority 
from a study by Murphy.[6] Considering the proportion 
of the expected incidence of residual paralysis was 5% 
with two-sided test size of 5% and statistical power of 
80% and the dropout rate of 10%, the total number of 
samples needed was 80 subjects.
Analyses were done on all subjects who had received 
treatment according to the protocol. Data were 
expressed in terms of numbers and percentages, 
medians and ranges, mean and standard deviations. 
The data between the two groups were analysed for 
differences using independent t-tests for numerical 
data and Fisher’s exact tests for categorical data. Data 
were analysed using SPSS 24 software computer 
program.
RESULTS
A total of 106 subjects were assessed for eligibility 
for this study. As shown in Figure 2, 26 subjects were 
excluded. Randomisation was done on 80 subjects. 
Two patients were not extubated, so measurements of 
TOF values in the recovery room were performed on 
39 subjects in each group. Six subjects were excluded 
from analysis because their inhalation anaesthesia 
agent was switched to isoflurane. Seventy-two 
subjects remained for per-protocol analysis. The study 
Figure 1: Reversal management after group allocation revealed at the start of skin closure
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was discontinued after achieving the target number of 
samples.
Characteristics of the subjects are presented in Table 1. 
Classification of open urology surgery was merged 
with gynaecology because there was only one patient 
in the urology subgroup. There were no differences 
between the two groups for sex, body mass index, ASA 
physical status and type of surgery. However, subjects 
in group A were younger than those in group B.
Both groups did not differ in the parameters of the 
duration of the anaesthesia procedure, the total 
rocuronium dose, the frequency of rocuronium 
administration, the time of last rocuronium 
administration and the total neostigmine dose, as 
presented in Table 2. The TOF ratio in the recovery 
room also did not differ between the two groups 
(mean	difference	=	−2.58; P = 0.053). However, the 
reversal-extubation time in group A was longer than 
in group B (mean difference = 5.08 min; P = 0.002).
Table 1: Patient characteristics
Variable Groups P (95%CI)
A (n=36) B (n=36)
Age (years) 39.14 (12.81) 45.53 (11.04) 0.026* (−12.01 to−0.77)
Male (n) 9 (25.0) 7 (19.4) 0.778 (−0.14 to 0.25)
Female (n) 27 (75.0) 29 (80.6)
Body mass index (kg/m2) 22.65 (3.89) 22.53 (3.58) 0.896 (−1.64 to 1.87)
The type of surgery (n)
Abdominal laparoscopic (n) 9 (25.0) 8 (22.2) 0.991
Open digestive (n) 12 (33.3) 12 (33.3)
Gynaecology and 
urology (n)
5 (13.9) 5 (13.9)
Others (n) 10 (27.8) 11 (30.6)
ASA physical status
ASA I (n) 8 (22.2) 9 (25.0) 0.781 (−0.22 to 0.17)
ASA II (n) 28 (77.8) 27 (75.0)
Data in number (%) or mean (SD).*P<0.05 is significant
Figure 2: Flow diagram of the progress of this study
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Six cases of residual paralysis in the recovery room 
were found in group A, whereas one case occurred in 
group B (16.7 versus 2.8%). There were no significant 
differences in the proportion of residual paralysis in the 
recovery room in both groups (P = 0.107). The absolute 
difference in the proportion of residual paralysis 
in the recovery room was 13.9% (95% confidence 
interval (CI): 1–27.2%). The equivalence test showed 
that the 95% CI value of this study was outside the 
range of equivalence margins [Figure 3], so that an 
optimal reversal strategy without TOF monitoring was 
not equivalent to a reversal strategy based on TOF 
quantitative monitoring.
Overall, no serious adverse event was found, as shown 
in Table 3. However, one subject experienced post 
extubation respiratory distress with wheezing. The 
subject received a dose of 3 mg neostigmine with a 
dose of atropine sulphate 0.5 mg. The condition was 
resolved after the added 0.25 mg atropine sulphate 
and deepened anaesthesia, without desaturation and 
respiratory distress in the recovery room.
DISCUSSION
Reversal strategy without TOF monitoring, although 
optimised, was not equivalent to reversal strategy 
using TOF monitoring. This finding supports the 
latest consensus regarding the use of perioperative 
TOF monitoring tools.[15] A study comparing the two 
strategies similar to our study showed almost the same 
incidence	of	paralysis	residual	(TOF	ratio	≤0.80)	with	
our results (3.3 versus 16.7% in the TOF group and 
clinical group, respectively).[16] However, all patients 
with residual paralysis from the clinical group had 
low TOF ratios (median: 0.69). The short mean of 
time from reversal to extubation (5 min) may explain 
the clinically unacceptable TOF ratio (<0.70) in the 
recovery room. Another study which used neostigmine 
without accordance to depth of blockade (50 µg/kg IV 
for every patient) and shorter reversal-extubation time 
of 9 min had similar incidence rate (15.4%), but had 
three events with a TOF ratio <0.70.[17]
In our study, one case of residual paralysis (TOF value 
0.87) occurred in group B even though the TOF value 
of 0.90 was confirmed before extubation. This result 
can be due to the paradox effect of muscle weakness 
by neostigmine or the variability of measuring 
devices.[18,19] However, recent evidence did not show 
a paradoxical effect when neostigmine was given after 
TOF	ratio	≥0.90	was	achieved.[20]
A total of 77% of subjects in group B achieved TOF 
ratio of 0.90 in 15 min and increased to 86% if 20 min 
elapsed. The longest reversal-extubation time in 
group A subjects who did not have residual paralysis 
was 30 min. This finding was supported in studies that 
reported neostigmine reversal required 30 min before 
Table 2: Perioperative data
Parameters Groups P (95% CI)
A B
Anaesthetic duration (min) 182 (87) 163 (68) 0.294 (−17 to 56)
Total rocuronium dose (mg) 45.8 (19.9) 42.9 (17.5) 0.511 (−5.9 to 11.7)
Frequency of rocuronium 
administration (n)
2.03 (1.94) 1.59 (1.21) 0.804 (−0.58 to 0.75)
Time of last rocuronium (min) 118.5 (72) 108.5 (56) 0.509 (−20.2 to 40.3)
Reversal‑extubation time (min) 17.4 (4.8) 12.3 (8.4) 0.002* (1.87 to 8.3)
Total neostigmine dose (mg) 1.28 (0.72) 1.29 (0.77) 0.956 (−0.36 to 0.34)
TOF value in recovery room (%) 92.89 (7.23) 95.47 (2.90) 0.053 (−5.20 to 0.29)
Residual paralysis (n/%) 6 (16.7) 1 (2.8) 0.107 (0.006 to 0.272)
Data in number (%) or mean (SD).*P<0.05 is significant
Figure 3: Hypothetical test of equivalence  in this study
Table 3: Adverse events
Parameters Group
A B
Respiratory adverse events (n/%) 0 (0) 0 (0)
Upper airway obstruction (n/%) 0 (0) 0 (0)
Mild hypoxemia (n/%) 0 (0) 0 (0)
Severe hypoxemia (n/%) 0 (0) 0 (0)
Respiratory distress (n/%) 0 (0) 1 (3)
Reintubation (n/%) 0 (0) 0 (0)
Postoperative nausea‑vomitus (n/%) 1 (3) 1 (3)
Severe adverse events (n/%) 0 (0) 0 (0)
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extubation.[21-24] Therefore, reversal strategy without 
TOF monitoring in inhalation anaesthesia should be 
optimised by extending the extubation time to 30 min 
after administration of neostigmine.
The use of sevoflurane and N2O in this study 
contributed to the prolongation of the duration of action 
of rocuronium, where as much as 91.6, 77.8 and 38.9% 
of group B subjects still had neuromuscular blockade 
despite the time of last rocuronium administration 
were 30, 60 and 120 min, respectively. This finding 
confirmed that the time since last rocuronium 
administration cannot be the basis to not reverse in 
patients receiving inhalation anaesthesia.
One incident of respiratory distress due to 
bronchospasm occurred in this study. Patients with 
history of asthma may still develop bronchospasm 
despite anticholinergic agent administration. Without 
history of asthma, some subjects experienced 
bronchospasm due to lack of atropine sulphate 
dosing, so as not to offset the high concentration of 
acetylcholine after 3 mg of neostigmine.[25]
No significant bradycardia (resulting in hypotension 
and requiring additional atropine) was reported in our 
study. Only 7 (10%) subjects had bradycardia within 
15 min of administration of neostigmine. Previous 
study using one dosage of neostigmine (50 µg/kg IV) 
reported that all subjects (n = 67) had bradycardia at 
10 min after reversal and 5 of them were considered 
clinically significant.[21] It implied that the accuracy of 
the neostigmine dose in our study avoids the risk of 
bradycardia.
This optimisation of reversal strategy has not been 
studied before. This study replicates most practices 
at the research site, namely the determination of 
recovery of neuromuscular function clinically, usage 
of rocuronium and sevoflurane. The 50-mA electric 
current stimulation used in this study is considered to 
provide supramaximal stimulation but not perceived 
as painful in patients recovering from anaesthesia.[22,26]
There were several limitations in this study. First, 
the age of the study subjects was different in the two 
groups. However, this age difference was not likely to 
affect the duration of action of rocuronium because 
only the infant and geriatric age groups were known 
to be associated with prolonged duration of action 
of rocuronium.[27,28] Second, controlled ventilation 
was not applied to every subject, only when there 
was indication. Therefore, time of last rocuronium 
administration in this study was almost 2 h. In 
addition, half of the subjects received rocuronium only 
once which was for facilitating intubation and 66.7% 
of subjects in group B got a reversal when the depth of 
neuromuscular blockade was at most mild. The equal 
depth of blockade at reversal was also found in most 
subjects in group A (83.4%). They might contribute to 
the low incidence of residual paralysis in this study. 
Third, we did not keep core and upper extremity in 
a specified range during anaesthesia procedure. Both 
central and peripheral surface cooling can reduce the 
measured TOF ratio.[29] Fourth, TOF value measuring 
was not normalised. There is a new recommendation to 
increase the value of the non-normalised TOF ratio to 
1.0 as the threshold for residual paralysis when using 
the accelerometer method.[30] Lastly, our study did not 
assess superiority of reversal using TOF monitoring to 
reversal without TOF monitoring.
This study showed that neostigmine dosing in 
accordance to the depth of blockade can be relied 
on as a reversal for rocuronium blockade. However, 
the assessment of the depth of blockade should be 
based on the quantitative TOF monitoring. When a 
TOF monitoring device is not available, neostigmine 
should be given to every patient who receives 
rocuronium because there is no guarantee that the 
patient will not have residual paralysis in the recovery 
room. For the next study, the reversal-extubation time 
should be extended to 30 min in the group without 
TOF monitoring. Normalisation measured-TOF value 
should also be performed in further studies.
CONCLUSIONS
The optimal reversal neostigmine strategy without 
TOF monitoring is not equivalent to reversal strategy 
based on quantitative TOF monitoring in order to 
prevent residual paralysis in the recovery room after 
the use of rocuronium as a neuromuscular blocking 
agent and sevoflurane as maintenance anaesthesia.
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